Cite

HARVARD Citation

    Danlos, F. et al. (2018). Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. European journal of cancer. pp. 21-29. [Online]. 
  
Back to record